Insmed price target raised to $88 from $68 at Truist

Truist raised the firm’s price target on Insmed to $88 from $68 and keeps a Buy rating on the shares. The firm is updating its model after the company’s Commercial Day presentation, boosting its FY25 revenue view to $639M from $545M and its FY26 view to $1.15B from $934M, modifying its brenso sales forecast for bronchiectasis to reflect the updated prevalence numbers and following the positive Phase 3 data while adjusting its assumed pricing from a $40K floor to the mid-point between Fasenra at $40K and Ofev at $96K, the analyst tells investors in a research note.